Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins

Article Radiology, Nuclear Medicine & Medical Imaging

Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer

Olga Bragina et al.

Summary: The study evaluated the safety, biodistribution, and dosimetry of Tc-99m-(HE)(3)-G3 in breast cancer patients, showing that the imaging method provides a low absorbed dose burden on patients and is safe and well-tolerated.

JOURNAL OF NUCLEAR MEDICINE (2022)

Add to Collection

Review Biochemistry & Molecular Biology

The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer

Olga D. Bragina et al.

Summary: This review examines the evolution of radionuclide diagnosis of HER2-positive breast cancer using various compounds as targeting modules. Clinical studies have shown that these compounds have good tolerability, rapid excretion, and the ability to differentiate tumor sites based on HER2/neu status.

ACTA NATURAE (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Phase I Study of 99mTc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer

Olga Bragina et al.

Summary: Radionuclide molecular imaging of HER2 expression with Tc-99(m)-ADAPT6 is safe and effective for stratifying breast cancer patients, with a protein dose of 500 μg being preferred for discrimination between HER2-positive and HER2-negative tumors. Further studies are warranted to explore the potential use of Tc-99(m)-ADAPT6 as an imaging probe in areas where PET imaging is not readily available.

JOURNAL OF NUCLEAR MEDICINE (2021)

Add to Collection

Review Oncology

The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer

Vladimir Tolmachev et al.

Summary: Targeting of HER2 using monoclonal antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors has shown success in extending survival of metastatic breast cancer patients with HER2-expressing tumors, with high HER2 expression serving as a predictive biomarker for such targeted therapies. Accurate determination of HER2 expression level is crucial for patient stratification, and non-invasive in vivo radionuclide molecular imaging of HER2 offers the potential for repetitive measurements to address issues of heterogeneous expression and changes in HER2 status during disease progression or treatment response.

SEMINARS IN CANCER BIOLOGY (2021)

Add to Collection

Article

EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT)

O. D. Bragina et al.

Siberian Journal of Oncology (2021)

Add to Collection

Article Medicine, General & Internal

Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use

O. D. Bragina et al.

Summary: The study investigated the clinical use of a radiopharmaceutical for the diagnosis of breast cancer with Her2/neu overexpression. Results showed promising potential for the radiopharmaceutical as a new additional method for diagnosing Her2-positive breast tumors.

BYULLETEN SIBIRSKOY MEDITSINY (2021)

Add to Collection

Review Chemistry, Medicinal